Abiopharma

🔍 Haskell Gregory W (Director)

Company: Innventure, Inc. (INV)

Report Date: 2026-04-02

Detailed Transactions and Holdings:

• Acquired 121,228 shares of Common Stock (Direct)
  Date: 2026-04-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 883,343.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 228,787 shares of Nonqualified Stock Option (right to buy) at $6.0 per share (Derivative)
  Date: 2026-04-02 | Code: A | Expires: 2036-04-02 | Exercise: 2027-04-02 | equity_swap_involved: 0 | shares_owned_after: 228,787.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: The Restricted Stock Units were granted to the Reporting Person under the Innventure, Inc. 2024 Equity and Incentive Compensation Plan (the "Plan"), and vest in three equal installments on April 2, 2027, April 2, 2028, and April 2, 2029, subject to the Reporting Person's continuous service to Innventure, Inc. (the Issuer") until the applicable vesting date.
• F2: The nonqualified stock options ("Stock Options"), exercisable solely in the Issuer's common stock, par value $0.0001 per share ("Common Stock") were granted by the Issuer to the Reporting Person on April 2, 2026 pursuant to the Plan. One-third of the shares of Common Stock underlying the Stock Options vest and become exercisable on April 2, 2027 and the remaining two-thirds of the shares of Common Stock underlying the Stock Options vest and become exercisable in eight substantially equal installments on each three-month anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer until the applicable vesting date. The Stock Options were granted as a premium-price stock options. The $6.00 exercise price exceeds the $4.64 closing price of the Issuer's Common Stock on the grant date.